Burning Rock Q2 Revenue Falls 9%, Loss Widens on Lab Weakness
BNR sits 71% above its 52-week low of $6.79 on elevated volume (2.0× avg).
Summary
Burning Rock's Q2 revenue fell 9% to RMB134.7M, missing the year-ago level, while net loss widened to RMB18.4M. The decline was driven by a 10% drop in central laboratory revenue as the company shifts toward in-hospital testing, and a 31.8% plunge in pharma services. In-hospital revenue grew 7.4%, but not enough to offset the declines. Operating expenses fell 3% on cost controls, but the top-line weakness is the story. This follows the 6-K filed this morning with the same figures; the news adds segment detail and confirms the negative trend. Watch for new product registration certificates in coming quarters, which management says will support long-term growth.
At the time of this announcement, BNR was trading at $11.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $126.1M. The 52-week trading range was $6.79 to $41.72. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.